IL-27, a cytokine, and IFN-λ1, a type III IFN, are coordinated to regulate virus replication through type I IFN

Journal of Immunology

Volumn 192, Issue 2, 2014, Pages 691-703

  Cao, Yanhua ^a   Zhang, Rui ^a   Zhang, Wei ^a   Zhu, Chengliang ^a   Yu, Yi ^a   Song, Yu ^a   Wang, Qing ^a   Bai, Lan ^a   Liu, Yingle ^a,b   Wu, Kailang ^a,b   Wu, Jianguo ^a,b  

^a WUHAN UNIVERSITY   (China)

^b Wuhan Institute of Biotechnology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 27; INTERLEUKIN 28 RECEPTOR 1; INTERLEUKIN 29; INTERLEUKIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLIGOADENYLATE SYNTHETASE 1; STAT1 PROTEIN; STAT2 PROTEIN; SYNTHETASE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ADULT; ARTICLE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA REPLICATION; DOWN REGULATION; ENZYME REGULATION; FEMALE; GENE EXPRESSION; HEPATITIS B VIRUS; HUMAN; IMMUNOREGULATION; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS CAPSID; VIRUS REPLICATION;

CELL LINE, TUMOR; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; HEP G2 CELLS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERON-ALPHA; INTERLEUKINS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN-10; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; UP-REGULATION; VIRUS REPLICATION;

EID: 84892707316     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300252     Document Type: Article

References (56)

1. Pflanz, S., J. C. Timans, J. Cheung, R. Rosales, H. Kanzler, J. Gilbert, L. Hibbert, T. Churakova, M. Travis, E. Vaisberg, et al. 2002. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16: 779-790. (Pubitemid 34786477)
2. Pflanz, S., L. Hibbert, J. Mattson, R. Rosales, E. Vaisberg, J. F. Bazan, J. H. Phillips, T. K. McClanahan, R. de Waal Malefyt, and R. A. Kastelein. 2004. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172: 2225-2231. (Pubitemid 38182370)
3. Chen, Q., N. Ghilardi, H. Wang, T. Baker, M. H. Xie, A. Gurney, I. S. Grewal, and F. J. de Sauvage. 2000. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407: 916-920.
4. Yoshida, H., M. Nakaya, and Y. Miyazaki. 2009. Interleukin 27: a double-edged sword for offense and defense. J. Leukoc. Biol. 86: 1295-1303.
5. Guzzo, C., A. Ayer, S. Basta, B. W. Banfield, and K. Gee. 2012. IL-27 enhances LPS-induced proinflammatory cytokine production via upregulation of TLR4 expression and signaling in human monocytes. J. Immunol. 188: 864-873.
6. Stumhofer, J. S., and C. A. Hunter. 2008. Advances in understanding the antiinflammatory properties of IL-27. Immunol. Lett. 117: 123-130.
7. Awasthi, A., Y. Carrier, J. P. Peron, E. Bettelli, M. Kamanaka, R. A. Flavell, V. K. Kuchroo, M. Oukka, and H. L. Weiner. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8: 1380-1389. (Pubitemid 350131175)
8. Fitzgerald, D. C., G. X. Zhang, M. El-Behi, Z. Fonseca-Kelly, H. Li, S. Yu, C. J. Saris, B. Gran, B. Ciric, and A. Rostami. 2007. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8: 1372-1379. (Pubitemid 350131174)
9. Stumhofer, J. S., J. S. Silver, A. Laurence, P. M. Porrett, T. H. Harris, L. A. Turka, M. Ernst, C. J. Saris, J. J. O'Shea, and C. A. Hunter. 2007. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8: 1363-1371. (Pubitemid 350131173)
10. Wojno, E. D., N. Hosken, J. S. Stumhofer, A. C. O'Hara, E. Mauldin, Q. Fang, L. A. Turka, S. D. Levin, and C. A. Hunter. 2011. A role for IL-27 in limiting T regulatory cell populations. J. Immunol. 187: 266-273.
11. Charlot-Rabiega, P., E. Bardel, C. Dietrich, R. Kastelein, and O. Devergne. 2011. Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells. J. Biol. Chem. 286: 27350-27362.
12. Greenwell-Wild, T., N. Vázquez, W. Jin, Z. Rangel, P. J. Munson, and S. M. Wahl. 2009. Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. Blood 114: 1864-1874.
13. Frank, A. C., X. Zhang, A. Katsounas, J. P. Bharucha, S. Kottilil, and T. Imamichi. 2010. Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J. Interferon Cytokine Res. 30: 427-431.
14. Salcedo, R., J. A. Hixon, J. K. Stauffer, R. Jalah, A. D. Brooks, T. Khan, R. M. Dai, L. Scheetz, E. Lincoln, T. C. Back, et al. 2009. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182: 4328-4338.
15. Cocco, C., N. Giuliani, E. Di Carlo, E. Ognio, P. Storti, M. Abeltino, C. Sorrentino, M. Ponzoni, D. Ribatti, and I. Airoldi. 2010. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin. Cancer Res. 16: 4188-4197.
16. Ho, M. Y., S. J. Leu, G. H. Sun, M. H. Tao, S. J. Tang, and K. H. Sun. 2009. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J. Immunol. 183: 6217-6226.
17. Yoshimoto, T., N. Morishima, I. Mizoguchi, M. Shimizu, H. Nagai, S. Oniki, M. Oka, C. Nishigori, and J. Mizuguchi. 2008. Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180: 6527-6535.
18. Niedbala, W., B. Cai, X. Wei, A. Patakas, B. P. Leung, I. B. McInnes, and F. Y. Liew. 2008. Interleukin 27 attenuates collagen-induced arthritis. Ann. Rheum. Dis. 67: 1474-1479.
19. Rajaiah, R., M. Puttabyatappa, S. K. Polumuri, and K. D. Moudgil. 2011. Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis. J. Biol. Chem. 286: 2817-2825.
20. Liu, L., Z. Cao, J. Chen, R. Li, Y. Cao, C. Zhu, K. Wu, J. Wu, F. Liu, and Y. Zhu. 2012. Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase A signaling. J. Biol. Chem. 287: 11899-11910.
21. Kawai, T., and S. Akira. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7: 131-137. (Pubitemid 43135878)
22. Sadler, A. J., and B. R. Williams. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8: 559-568. (Pubitemid 351913674)
23. Kotenko, S. V., G. Gallagher, V. V. Baurin, A. Lewis-Antes, M. Shen, N. K. Shah, J. A. Langer, F. Sheikh, H. Dickensheets, and R. P. Donnelly. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77. (Pubitemid 36109115)
24. Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, T. E. Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4: 63-68. (Pubitemid 36104710)
25. Coccia, E. M., M. Severa, E. Giacomini, D. Monneron, M. E. Remoli, I. Julkunen, M. Cella, R. Lande, and G. Uzé. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and l interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34: 796-805. (Pubitemid 39255927)
26. Thomson, S. J., F. G. Goh, H. Banks, T. Krausgruber, S. V. Kotenko, B. M. Foxwell, and I. A. Udalova. 2009. The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc. Natl. Acad. Sci. USA 106: 11564-11569.
27. Dumoutier, L., A. Tounsi, T. Michiels, C. Sommereyns, S. V. Kotenko, and J. C. Renauld. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J. Biol. Chem. 279: 32269-32274. (Pubitemid 39014676)
28. Doyle, S. E., H. Schreckhise, K. Khuu-Duong, K. Henderson, R. Rosler, H. Storey, L. Yao, H. Liu, F. Barahmand-pour, P. Sivakumar, et al. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906. (Pubitemid 46489554)
29. Ank, N., H. West, and S. R. Paludan. 2006. IFN-l: novel antiviral cytokines. J. Interferon Cytokine Res. 26: 373-379.
30. Robek, M. D., B. S. Boyd, and F. V. Chisari. 2005. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79: 3851-3854. (Pubitemid 40327973)
31. Wang, J., R. Oberley-Deegan, S. Wang, M. Nikrad, C. J. Funk, K. L. Hartshorn, and R. J. Mason. 2009. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-l 1) in response to influenza A infection. J. Immunol. 182: 1296-1304.
32. Ganem, D., and A. M. Prince. 2004. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 350: 1118-1129. (Pubitemid 38298992)
33. Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5: 215-229. (Pubitemid 40364823)
34. Wieland, S. F., L. G. Guidotti, and F. V. Chisari. 2000. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol. 74: 4165-4173. (Pubitemid 30214422)
35. Guidotti, L. G., and F. V. Chisari. 1999. Cytokine-induced viral purging-role in viral pathogenesis. Curr. Opin. Microbiol. 2: 388-391.
36. Zhu, C., R. Zhang, L. Liu, S. T. Rasool, Y. Mu, W. Sun, Q. Hao, F. Liu, Y. Zhu, and J. Wu. 2009. Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro. Clin. Immunol. 131: 92-97.
37. Yu, Y., R. Gong, Y. Mu, Y. Chen, C. Zhu, Z. Sun, M. Chen, Y. Liu, Y. Zhu, and J. Wu. 2011. Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. J. Immunol. 187: 4844-4860.
38. Cooksley, W. G. 2004. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin. Liver Dis. 24(Suppl. 1): 45-53. (Pubitemid 38738358)
39. Marcellin, P., G. K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin, Z. M. Lu, T. Piratvisuth, G. Germanidis, C. Yurdaydin, et al; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAgnegative chronic hepatitis B. N. Engl. J. Med. 351: 1206-1217. (Pubitemid 39296307)
40. Xie, Y. H., R. Hong, W. Liu, J. Liu, and J. W. Zhai. 2010. Development of novel therapeutics for chronic hepatitis B. Virol. Sin. 25: 294-300.
41. Mennechet, F. J., and G. Uzé. 2006. Interferon-l-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107: 4417-4423. (Pubitemid 43801368)
42. Keasler, V. V., A. J. Hodgson, C. R. Madden, and B. L. Slagle. 2007. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J. Virol. 81: 2656-2662. (Pubitemid 46447031)
43. Wang, H. L., H. Y. Zhang, Z. L. Zhai, and X. Zhou. 2012. The correlation between hepatitis B virus infection and IL-27. Biomed. Mater. Eng. 22: 187-193.
44. Bender, H., M. Y. Wiesinger, C. Nordhoff, C. Schoenherr, C. Haan, S. Ludwig, R. Weiskirchen, N. Kato, P. C. Heinrich, and S. Haan. 2009. Interleukin-27 displays interferon-γ-like functions in human hepatoma cells and hepatocytes. Hepatology 50: 585-591.
45. Honda, K., and T. Taniguchi. 2006. IRFs: master regulators of signalling by Tolllike receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6: 644-658. (Pubitemid 44298214)
46. Hölscher, C., A. Hölscher, D. Rückerl, T. Yoshimoto, H. Yoshida, T. Mak, C. Saris, and S. Ehlers. 2005. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J. Immunol. 174: 3534-3544. (Pubitemid 40354062)
47. Artis, D., A. Villarino, M. Silverman, W. He, E. M. Thornton, S. Mu, S. Summer, T. M. Covey, E. Huang, H. Yoshida, et al. 2004. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 173: 5626-5634. (Pubitemid 39392150)
48. Villarino, A. V., E. Huang, and C. A. Hunter. 2004. Understanding the pro-and anti-inflammatory properties of IL-27. J. Immunol. 173: 715-720. (Pubitemid 38924243)
49. Khoo, S., S. C. Griffen, Y. Xia, R. J. Baer, M. S. German, and M. H. Cobb. 2003. Regulation of insulin gene transcription by ERK1 and ERK2 in pancreatic beta cells. J. Biol. Chem. 278: 32969-32977. (Pubitemid 37055741)
50. Kao, J. T., H. C. Lai, S. M. Tsai, P. C. Lin, P. H. Chuang, C. J. Yu, K. S. Cheng, W. P. Su, P. N. Hsu, C. Y. Peng, and Y. Y. Wu. 2012. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients. Liver Int. 32: 928-936.
51. Fakruddin, J. M., R. A. Lempicki, R. J. Gorelick, J. Yang, J. W. Adelsberger, A. J. Garcia-Pineres, L. A. Pinto, H. C. Lane, and T. Imamichi. 2007. Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood 109: 1841-1849. (Pubitemid 46348178)
52. Imamichi, T., J. Yang, D. W. Huang, T. W. Brann, B. A. Fullmer, J. W. Adelsberger, R. A. Lempicki, M. W. Baseler, and H. C. Lane. 2008. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. AIDS 22: 39-45. (Pubitemid 350294876)
53. Patel, K., and J. G. McHutchison. 2004. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve. Clin. J. Med. 71(Suppl. 3): S8-S12. (Pubitemid 41315600)
54. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Gonçales, Jr., D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975-982.
55. Dusheiko, G. 1997. Side effects of alpha interferon in chronic hepatitis C. Hepatology 26(3, Suppl. 1)112S-121S. (Pubitemid 27388083)
56. Maddrey, W. C. 2000. Hepatitis B: an important public health issue. J. Med. Virol. 61: 362-366. (Pubitemid 30368539)